Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Investing Activities (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Cash from Investing Activities for 5 consecutive years, with -$70.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 208.46% year-over-year to -$70.8 million, compared with a TTM value of -$189.0 million through Dec 2025, down 601.68%, and an annual FY2025 reading of -$189.0 million, down 601.68% over the prior year.
  • Cash from Investing Activities was -$70.8 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from -$62.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $86.0 million in Q2 2021 and bottomed at -$70.8 million in Q4 2025.
  • Average Cash from Investing Activities over 5 years is -$3.0 million, with a median of -$9.3 million recorded in 2023.
  • The sharpest move saw Cash from Investing Activities surged 538.38% in 2024, then tumbled 888.58% in 2025.
  • Year by year, Cash from Investing Activities stood at -$50.0 million in 2021, then grew by 14.75% to -$42.7 million in 2022, then soared by 65.09% to -$14.9 million in 2023, then soared by 538.38% to $65.3 million in 2024, then tumbled by 208.46% to -$70.8 million in 2025.
  • Business Quant data shows Cash from Investing Activities for KNSA at -$70.8 million in Q4 2025, -$62.8 million in Q3 2025, and -$3.9 million in Q2 2025.